Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (201 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subject hasalzheimerthe subjectmridisorder
  Phrases that lowered it: participantsparticipanthealthypregnantblood
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 45.8% (raises risk) · Sponsor's track record
• Primary purpose: not given (lowers risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Disease area, neurology: Yes (raises risk) · Disease area
• Phase: 1 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Sponsor's past trials: 24 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 7 (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Maximum age: 90 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss NCT03587649 · started 2018 · scored riskier than 25% of active trials completed
• Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers NCT03903549 · started 2022 · scored riskier than 7% of active trials completed
• A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions NCT00870974 · started 2009 · scored riskier than 28% of active trials completed
• Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a NCT01461083 · started 2011 · scored riskier than 25% of active trials completed
• Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease NCT02370524 · started 2015 · scored riskier than 23% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.